| Characteristics . | All Episodes (n = 103) . | PIV (n = 48) . | RSV (n = 33) . | MPV (n = 22) . | P Value . |
|---|---|---|---|---|---|
| Age, median years (range) | 52.3 (19.9–70.6) | 51.6 (22.3–68.2) | 52.5 (19.9–70.6) | 53.6 (26.7–69.2) | .509 |
| Male, n (%) | 72 (69.9) | 34 (70.8) | 24 (72.7) | 14 (63.6) | .786 |
| Female, n (%) | 31 (30.1) | 14 (29.2) | 9 (27.3) | 8 (36.4) | |
| Time post-alloHCT, median (IQR) | .166 | ||||
| Underlying disease | 518 (212–1014) | 627.5 (234.5–1252.5) | 382 (162–709) | 503.5 (298.8–1066.8) | .859 |
| Acute lymphoid leukemia, n (%) | 17 (16.5) | 8 (16.7) | 5 (15.2) | 4 (18.2) | |
| Acute myeloid leukemia, n (%) | 31 (30.1) | 15 (31.3) | 9 (27.3) | 7 (31.8) | |
| Chronic myeloid leukemia, n (%) | 7 (6.8) | 2 (4.2) | 2 (6.1) | 3 (13.6) | |
| Chronic lymphoid leukemia, n (%) | 6 (5.8) | 2 (4.2) | 3 (9.1) | 1 (4.5) | |
| Myelodysplastic syndrome n (%) | 8 (7.8) | 4 (8.3) | 4 (12.1) | 0 | |
| Myeloproliferative syndrome, n (%) | 6 (5.8) | 2 (4.2) | 1 (3.0) | 3 (13.6) | |
| Multiple myeloma, n (%) | 13 (12.6) | 6 (12.5) | 4 (12.1) | 3 (13.6) | |
| Non-Hodgkin lymphoma, n (%) | 11 (10.7) | 7 (14.6) | 3 (9.1) | 1 (4.5) | |
| Primary immunodeficiencies, n (%) | 3 (2.9) | 2 (4.2) | 1 (3.0) | 0 | |
| Aplastic anemia, n (%) | 1 (1.0) | 0 | 0 | 1 (4.5) | |
| Type of transplant | .088 | ||||
| HLA-matched related, n (%) | 42 (40.8) | 24 (50.0) | 12 (36.4) | 6 (27.3) | |
| HLA-matched unrelated, n (%) | 36 (35.0) | 16 (33.3) | 9 (27.3) | 11 (50.0) | |
| HLA-mismatched related, n (%) | 5 (4.9) | 0 | 3 (9.1) | 2 (9.1) | |
| HLA-mismatched unrelated, n (%) | 20 (19.4) | 8 (16.7) | 9 (27.3) | 3 (13.6) | |
| Cytomegalovirus Status | .229 | ||||
| D/R−/−, n (%) | 39 (37.7) | 15 (31.3) | 12 (36.4) | 12 (54.5) | |
| D/R−/+, n (%) | 31 (30.1) | 17 (35.4) | 9 (27.3) | 5 (22.7) | |
| D/R+/−, n (%) | 5 (4.9) | 1 (2.1) | 4 (12.1) | 0 | |
| D/R+/+, n (%) | 28 (27.2) | 15 (31.3) | 8 (24.2) | 5 (22.7) | |
| Stem Cell Source | 1.000 | ||||
| Bone marrow, n (%) | 0 | 0 | 0 | 0 | |
| Peripheral blood, n (%) | 102 (99.0) | 47 (97.9) | 33 (100.0) | 22 (100.0) | |
| Umbilical cord blood, n (%) | 1 (1.0) | 1 (2.1) | 0 | 0 | |
| Conditioning Regimen | .840 | ||||
| Myeloablative, n (%) | 60 (58.3) | 27 (56.3) | 19 (57.6) | 14 (63.6) | |
| Non-myeloablative, n (%) | 43 (41.7) | 21 (43.8) | 14 (42.4) | 8 (36.4) | |
| Hematological Condition at RTID Diagnosis | |||||
| Complete remission | 87 (84.5) | 40 (83.3) | 28 (84.8) | 19 (86.4) | .422 |
| GvHD | 64 (62.1) | 29 (60.4) | 19 (57.6) | 16 (72.7) | .505 |
| GvHD grade ≥ 2 | 38 (36.9) | 17 (35.4) | 9 (27.3) | 12 (54.5) | .236 |
| Bronchiolitis obliterans, n (%) | 23 (22.3) | 13 (27.1) | 4 (12.1) | 6 (27.3) | .241 |
| Immunosuppressives | .139 | ||||
| Calcineurin inhibitors (TAC; CYA), n (%) | 53 (51.5) | 22 (45.8) | 19 (57.6) | 12 (54.5) | |
| Mycophenolate mofetil, n (%) | 3 (2.9) | 2 (4.2) | 1 (3.0) | 0 | |
| CNI + MMF, n (%) | 25 (24.3) | 11 (22.9) | 5 (15.2) | 9 (40.9) | |
| Steroids, n (%) | 49 (47.6) | 24 (50.0) | 14 (42.4) | 11 (50.0) | |
| Characteristics . | All Episodes (n = 103) . | PIV (n = 48) . | RSV (n = 33) . | MPV (n = 22) . | P Value . |
|---|---|---|---|---|---|
| Age, median years (range) | 52.3 (19.9–70.6) | 51.6 (22.3–68.2) | 52.5 (19.9–70.6) | 53.6 (26.7–69.2) | .509 |
| Male, n (%) | 72 (69.9) | 34 (70.8) | 24 (72.7) | 14 (63.6) | .786 |
| Female, n (%) | 31 (30.1) | 14 (29.2) | 9 (27.3) | 8 (36.4) | |
| Time post-alloHCT, median (IQR) | .166 | ||||
| Underlying disease | 518 (212–1014) | 627.5 (234.5–1252.5) | 382 (162–709) | 503.5 (298.8–1066.8) | .859 |
| Acute lymphoid leukemia, n (%) | 17 (16.5) | 8 (16.7) | 5 (15.2) | 4 (18.2) | |
| Acute myeloid leukemia, n (%) | 31 (30.1) | 15 (31.3) | 9 (27.3) | 7 (31.8) | |
| Chronic myeloid leukemia, n (%) | 7 (6.8) | 2 (4.2) | 2 (6.1) | 3 (13.6) | |
| Chronic lymphoid leukemia, n (%) | 6 (5.8) | 2 (4.2) | 3 (9.1) | 1 (4.5) | |
| Myelodysplastic syndrome n (%) | 8 (7.8) | 4 (8.3) | 4 (12.1) | 0 | |
| Myeloproliferative syndrome, n (%) | 6 (5.8) | 2 (4.2) | 1 (3.0) | 3 (13.6) | |
| Multiple myeloma, n (%) | 13 (12.6) | 6 (12.5) | 4 (12.1) | 3 (13.6) | |
| Non-Hodgkin lymphoma, n (%) | 11 (10.7) | 7 (14.6) | 3 (9.1) | 1 (4.5) | |
| Primary immunodeficiencies, n (%) | 3 (2.9) | 2 (4.2) | 1 (3.0) | 0 | |
| Aplastic anemia, n (%) | 1 (1.0) | 0 | 0 | 1 (4.5) | |
| Type of transplant | .088 | ||||
| HLA-matched related, n (%) | 42 (40.8) | 24 (50.0) | 12 (36.4) | 6 (27.3) | |
| HLA-matched unrelated, n (%) | 36 (35.0) | 16 (33.3) | 9 (27.3) | 11 (50.0) | |
| HLA-mismatched related, n (%) | 5 (4.9) | 0 | 3 (9.1) | 2 (9.1) | |
| HLA-mismatched unrelated, n (%) | 20 (19.4) | 8 (16.7) | 9 (27.3) | 3 (13.6) | |
| Cytomegalovirus Status | .229 | ||||
| D/R−/−, n (%) | 39 (37.7) | 15 (31.3) | 12 (36.4) | 12 (54.5) | |
| D/R−/+, n (%) | 31 (30.1) | 17 (35.4) | 9 (27.3) | 5 (22.7) | |
| D/R+/−, n (%) | 5 (4.9) | 1 (2.1) | 4 (12.1) | 0 | |
| D/R+/+, n (%) | 28 (27.2) | 15 (31.3) | 8 (24.2) | 5 (22.7) | |
| Stem Cell Source | 1.000 | ||||
| Bone marrow, n (%) | 0 | 0 | 0 | 0 | |
| Peripheral blood, n (%) | 102 (99.0) | 47 (97.9) | 33 (100.0) | 22 (100.0) | |
| Umbilical cord blood, n (%) | 1 (1.0) | 1 (2.1) | 0 | 0 | |
| Conditioning Regimen | .840 | ||||
| Myeloablative, n (%) | 60 (58.3) | 27 (56.3) | 19 (57.6) | 14 (63.6) | |
| Non-myeloablative, n (%) | 43 (41.7) | 21 (43.8) | 14 (42.4) | 8 (36.4) | |
| Hematological Condition at RTID Diagnosis | |||||
| Complete remission | 87 (84.5) | 40 (83.3) | 28 (84.8) | 19 (86.4) | .422 |
| GvHD | 64 (62.1) | 29 (60.4) | 19 (57.6) | 16 (72.7) | .505 |
| GvHD grade ≥ 2 | 38 (36.9) | 17 (35.4) | 9 (27.3) | 12 (54.5) | .236 |
| Bronchiolitis obliterans, n (%) | 23 (22.3) | 13 (27.1) | 4 (12.1) | 6 (27.3) | .241 |
| Immunosuppressives | .139 | ||||
| Calcineurin inhibitors (TAC; CYA), n (%) | 53 (51.5) | 22 (45.8) | 19 (57.6) | 12 (54.5) | |
| Mycophenolate mofetil, n (%) | 3 (2.9) | 2 (4.2) | 1 (3.0) | 0 | |
| CNI + MMF, n (%) | 25 (24.3) | 11 (22.9) | 5 (15.2) | 9 (40.9) | |
| Steroids, n (%) | 49 (47.6) | 24 (50.0) | 14 (42.4) | 11 (50.0) | |
Abbreviations: alloHCT, allogeneic hematopoetic cell transplantation; CNI, calcineurin inhibitors; CYA, cyclosporine A; D/R, donor/recipient; GvHD, Graft-versus-host disease; HLA, human leucocyte antigen; IQR, interquartile range; MMF, mycophenolate mofetil; MPV, human metapneumovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RTID, respiratory tract infectious disease; TAC, tacrolimus.
| Characteristics . | All Episodes (n = 103) . | PIV (n = 48) . | RSV (n = 33) . | MPV (n = 22) . | P Value . |
|---|---|---|---|---|---|
| Age, median years (range) | 52.3 (19.9–70.6) | 51.6 (22.3–68.2) | 52.5 (19.9–70.6) | 53.6 (26.7–69.2) | .509 |
| Male, n (%) | 72 (69.9) | 34 (70.8) | 24 (72.7) | 14 (63.6) | .786 |
| Female, n (%) | 31 (30.1) | 14 (29.2) | 9 (27.3) | 8 (36.4) | |
| Time post-alloHCT, median (IQR) | .166 | ||||
| Underlying disease | 518 (212–1014) | 627.5 (234.5–1252.5) | 382 (162–709) | 503.5 (298.8–1066.8) | .859 |
| Acute lymphoid leukemia, n (%) | 17 (16.5) | 8 (16.7) | 5 (15.2) | 4 (18.2) | |
| Acute myeloid leukemia, n (%) | 31 (30.1) | 15 (31.3) | 9 (27.3) | 7 (31.8) | |
| Chronic myeloid leukemia, n (%) | 7 (6.8) | 2 (4.2) | 2 (6.1) | 3 (13.6) | |
| Chronic lymphoid leukemia, n (%) | 6 (5.8) | 2 (4.2) | 3 (9.1) | 1 (4.5) | |
| Myelodysplastic syndrome n (%) | 8 (7.8) | 4 (8.3) | 4 (12.1) | 0 | |
| Myeloproliferative syndrome, n (%) | 6 (5.8) | 2 (4.2) | 1 (3.0) | 3 (13.6) | |
| Multiple myeloma, n (%) | 13 (12.6) | 6 (12.5) | 4 (12.1) | 3 (13.6) | |
| Non-Hodgkin lymphoma, n (%) | 11 (10.7) | 7 (14.6) | 3 (9.1) | 1 (4.5) | |
| Primary immunodeficiencies, n (%) | 3 (2.9) | 2 (4.2) | 1 (3.0) | 0 | |
| Aplastic anemia, n (%) | 1 (1.0) | 0 | 0 | 1 (4.5) | |
| Type of transplant | .088 | ||||
| HLA-matched related, n (%) | 42 (40.8) | 24 (50.0) | 12 (36.4) | 6 (27.3) | |
| HLA-matched unrelated, n (%) | 36 (35.0) | 16 (33.3) | 9 (27.3) | 11 (50.0) | |
| HLA-mismatched related, n (%) | 5 (4.9) | 0 | 3 (9.1) | 2 (9.1) | |
| HLA-mismatched unrelated, n (%) | 20 (19.4) | 8 (16.7) | 9 (27.3) | 3 (13.6) | |
| Cytomegalovirus Status | .229 | ||||
| D/R−/−, n (%) | 39 (37.7) | 15 (31.3) | 12 (36.4) | 12 (54.5) | |
| D/R−/+, n (%) | 31 (30.1) | 17 (35.4) | 9 (27.3) | 5 (22.7) | |
| D/R+/−, n (%) | 5 (4.9) | 1 (2.1) | 4 (12.1) | 0 | |
| D/R+/+, n (%) | 28 (27.2) | 15 (31.3) | 8 (24.2) | 5 (22.7) | |
| Stem Cell Source | 1.000 | ||||
| Bone marrow, n (%) | 0 | 0 | 0 | 0 | |
| Peripheral blood, n (%) | 102 (99.0) | 47 (97.9) | 33 (100.0) | 22 (100.0) | |
| Umbilical cord blood, n (%) | 1 (1.0) | 1 (2.1) | 0 | 0 | |
| Conditioning Regimen | .840 | ||||
| Myeloablative, n (%) | 60 (58.3) | 27 (56.3) | 19 (57.6) | 14 (63.6) | |
| Non-myeloablative, n (%) | 43 (41.7) | 21 (43.8) | 14 (42.4) | 8 (36.4) | |
| Hematological Condition at RTID Diagnosis | |||||
| Complete remission | 87 (84.5) | 40 (83.3) | 28 (84.8) | 19 (86.4) | .422 |
| GvHD | 64 (62.1) | 29 (60.4) | 19 (57.6) | 16 (72.7) | .505 |
| GvHD grade ≥ 2 | 38 (36.9) | 17 (35.4) | 9 (27.3) | 12 (54.5) | .236 |
| Bronchiolitis obliterans, n (%) | 23 (22.3) | 13 (27.1) | 4 (12.1) | 6 (27.3) | .241 |
| Immunosuppressives | .139 | ||||
| Calcineurin inhibitors (TAC; CYA), n (%) | 53 (51.5) | 22 (45.8) | 19 (57.6) | 12 (54.5) | |
| Mycophenolate mofetil, n (%) | 3 (2.9) | 2 (4.2) | 1 (3.0) | 0 | |
| CNI + MMF, n (%) | 25 (24.3) | 11 (22.9) | 5 (15.2) | 9 (40.9) | |
| Steroids, n (%) | 49 (47.6) | 24 (50.0) | 14 (42.4) | 11 (50.0) | |
| Characteristics . | All Episodes (n = 103) . | PIV (n = 48) . | RSV (n = 33) . | MPV (n = 22) . | P Value . |
|---|---|---|---|---|---|
| Age, median years (range) | 52.3 (19.9–70.6) | 51.6 (22.3–68.2) | 52.5 (19.9–70.6) | 53.6 (26.7–69.2) | .509 |
| Male, n (%) | 72 (69.9) | 34 (70.8) | 24 (72.7) | 14 (63.6) | .786 |
| Female, n (%) | 31 (30.1) | 14 (29.2) | 9 (27.3) | 8 (36.4) | |
| Time post-alloHCT, median (IQR) | .166 | ||||
| Underlying disease | 518 (212–1014) | 627.5 (234.5–1252.5) | 382 (162–709) | 503.5 (298.8–1066.8) | .859 |
| Acute lymphoid leukemia, n (%) | 17 (16.5) | 8 (16.7) | 5 (15.2) | 4 (18.2) | |
| Acute myeloid leukemia, n (%) | 31 (30.1) | 15 (31.3) | 9 (27.3) | 7 (31.8) | |
| Chronic myeloid leukemia, n (%) | 7 (6.8) | 2 (4.2) | 2 (6.1) | 3 (13.6) | |
| Chronic lymphoid leukemia, n (%) | 6 (5.8) | 2 (4.2) | 3 (9.1) | 1 (4.5) | |
| Myelodysplastic syndrome n (%) | 8 (7.8) | 4 (8.3) | 4 (12.1) | 0 | |
| Myeloproliferative syndrome, n (%) | 6 (5.8) | 2 (4.2) | 1 (3.0) | 3 (13.6) | |
| Multiple myeloma, n (%) | 13 (12.6) | 6 (12.5) | 4 (12.1) | 3 (13.6) | |
| Non-Hodgkin lymphoma, n (%) | 11 (10.7) | 7 (14.6) | 3 (9.1) | 1 (4.5) | |
| Primary immunodeficiencies, n (%) | 3 (2.9) | 2 (4.2) | 1 (3.0) | 0 | |
| Aplastic anemia, n (%) | 1 (1.0) | 0 | 0 | 1 (4.5) | |
| Type of transplant | .088 | ||||
| HLA-matched related, n (%) | 42 (40.8) | 24 (50.0) | 12 (36.4) | 6 (27.3) | |
| HLA-matched unrelated, n (%) | 36 (35.0) | 16 (33.3) | 9 (27.3) | 11 (50.0) | |
| HLA-mismatched related, n (%) | 5 (4.9) | 0 | 3 (9.1) | 2 (9.1) | |
| HLA-mismatched unrelated, n (%) | 20 (19.4) | 8 (16.7) | 9 (27.3) | 3 (13.6) | |
| Cytomegalovirus Status | .229 | ||||
| D/R−/−, n (%) | 39 (37.7) | 15 (31.3) | 12 (36.4) | 12 (54.5) | |
| D/R−/+, n (%) | 31 (30.1) | 17 (35.4) | 9 (27.3) | 5 (22.7) | |
| D/R+/−, n (%) | 5 (4.9) | 1 (2.1) | 4 (12.1) | 0 | |
| D/R+/+, n (%) | 28 (27.2) | 15 (31.3) | 8 (24.2) | 5 (22.7) | |
| Stem Cell Source | 1.000 | ||||
| Bone marrow, n (%) | 0 | 0 | 0 | 0 | |
| Peripheral blood, n (%) | 102 (99.0) | 47 (97.9) | 33 (100.0) | 22 (100.0) | |
| Umbilical cord blood, n (%) | 1 (1.0) | 1 (2.1) | 0 | 0 | |
| Conditioning Regimen | .840 | ||||
| Myeloablative, n (%) | 60 (58.3) | 27 (56.3) | 19 (57.6) | 14 (63.6) | |
| Non-myeloablative, n (%) | 43 (41.7) | 21 (43.8) | 14 (42.4) | 8 (36.4) | |
| Hematological Condition at RTID Diagnosis | |||||
| Complete remission | 87 (84.5) | 40 (83.3) | 28 (84.8) | 19 (86.4) | .422 |
| GvHD | 64 (62.1) | 29 (60.4) | 19 (57.6) | 16 (72.7) | .505 |
| GvHD grade ≥ 2 | 38 (36.9) | 17 (35.4) | 9 (27.3) | 12 (54.5) | .236 |
| Bronchiolitis obliterans, n (%) | 23 (22.3) | 13 (27.1) | 4 (12.1) | 6 (27.3) | .241 |
| Immunosuppressives | .139 | ||||
| Calcineurin inhibitors (TAC; CYA), n (%) | 53 (51.5) | 22 (45.8) | 19 (57.6) | 12 (54.5) | |
| Mycophenolate mofetil, n (%) | 3 (2.9) | 2 (4.2) | 1 (3.0) | 0 | |
| CNI + MMF, n (%) | 25 (24.3) | 11 (22.9) | 5 (15.2) | 9 (40.9) | |
| Steroids, n (%) | 49 (47.6) | 24 (50.0) | 14 (42.4) | 11 (50.0) | |
Abbreviations: alloHCT, allogeneic hematopoetic cell transplantation; CNI, calcineurin inhibitors; CYA, cyclosporine A; D/R, donor/recipient; GvHD, Graft-versus-host disease; HLA, human leucocyte antigen; IQR, interquartile range; MMF, mycophenolate mofetil; MPV, human metapneumovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RTID, respiratory tract infectious disease; TAC, tacrolimus.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
